Why the study?
Brentuximab vedotin with chemotherapy is effective for Hodgkin lymphoma, but increased use has revealed novel, unexpected toxicities including cardiotoxicity.
Does Brentuximab vedotin with chemotherapy cause cardiotoxicity in patients with Hodgkin Lymphoma?
Does Brentuximab vedotin with chemotherapy cause cardiotoxicity in patients with Hodgkin Lymphoma?
Brentuximab vedotin combined with chemotherapy for Hodgkin Lymphoma may be associated with unexpected cardiotoxicity, warranting vigilant monitoring.
May warrant cardiac monitoring with BV-chemotherapy; leaves open incidence, mechanisms, and long-term safety.
Brentuximab vedotin (BV) with chemotherapy is a novel and an effective treatment for Hodgkin Lymphoma (HL) but is associated with increased rates of peripheral neuropathy and neutropenia. Since its increased use, novel adverse effects of the regimen have come to light, including unexpected toxicities. We report a case of BV-chemotherapy-induced cardiotoxicity, highlighting the need for vigilant monitoring and further research into the risk factors, mechanisms, and long-term safety profile of this therapy.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: